DK1362600T3 - Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis - Google Patents

Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis

Info

Publication number
DK1362600T3
DK1362600T3 DK02711351T DK02711351T DK1362600T3 DK 1362600 T3 DK1362600 T3 DK 1362600T3 DK 02711351 T DK02711351 T DK 02711351T DK 02711351 T DK02711351 T DK 02711351T DK 1362600 T3 DK1362600 T3 DK 1362600T3
Authority
DK
Denmark
Prior art keywords
decoy
stat
atopic dermatitis
traps
treatment
Prior art date
Application number
DK02711351T
Other languages
Danish (da)
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Application granted granted Critical
Publication of DK1362600T3 publication Critical patent/DK1362600T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02711351T 2001-02-20 2002-02-06 Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis DK1362600T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20
PCT/JP2002/000990 WO2002066070A1 (fr) 2001-02-20 2002-02-06 Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe

Publications (1)

Publication Number Publication Date
DK1362600T3 true DK1362600T3 (da) 2008-07-28

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02711351T DK1362600T3 (da) 2001-02-20 2002-02-06 Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis

Country Status (11)

Country Link
US (2) US9012417B2 (enExample)
EP (2) EP1362600B1 (enExample)
JP (2) JP3778357B2 (enExample)
AT (1) ATE390938T1 (enExample)
CY (1) CY1108165T1 (enExample)
DE (1) DE60225899T2 (enExample)
DK (1) DK1362600T3 (enExample)
ES (1) ES2307733T3 (enExample)
PT (1) PT1362600E (enExample)
TW (1) TWI308492B (enExample)
WO (1) WO2002066070A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395065T1 (de) * 1993-10-29 2008-05-15 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
US20070066935A1 (en) * 2003-05-09 2007-03-22 Ryuichi Morishita Needleless syringe having medical agent accomodated therein
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
CN1842349A (zh) * 2003-08-29 2006-10-04 安琪士摩奇株式会社 使用无针注射器进行皮肤疾病基因治疗
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
US7927873B2 (en) 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
WO2006034433A2 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
US8067384B2 (en) 2004-10-22 2011-11-29 Anges Mg, Inc. Chimera (double) decoy
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
JPWO2006132204A1 (ja) 2005-06-06 2009-01-08 アンジェスＭｇ株式会社 転写因子デコイ
JP2009502913A (ja) * 2005-07-27 2009-01-29 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 調節因子
CA2634291A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
WO2008099906A1 (ja) 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
JP5674020B2 (ja) * 2008-03-28 2015-02-18 アンジェスＭｇ株式会社 転写因子デコイを有効成分とする外用剤組成物
AU2013259402B2 (en) 2012-05-10 2017-12-21 Adynxx, Inc. Formulations for the delivery of active ingredients
EP3180434B1 (en) 2014-08-15 2019-07-17 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
ATE395065T1 (de) 1993-10-29 2008-05-15 Brigham & Womens Hospital Therapeutische verwendung von cis-element-fallen in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5869088A (en) * 1994-10-24 1999-02-09 Nikken Chemicals Co., Ltd Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline
ES2285712T3 (es) * 1995-05-12 2007-11-16 Anges Mg, Inc. Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
KR19990071523A (ko) * 1995-11-21 1999-09-27 해리 에이. 루스제 Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법
DE69834038D1 (de) * 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
JP2001055331A (ja) 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
CN100542614C (zh) * 2000-02-02 2009-09-23 安增子摩祺株式会社 用于基因转移的病毒包膜载体
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
EP1470826B1 (en) * 2002-02-01 2009-01-28 AnGes MG, Inc. Decoy-containing pharmaceutical compositions for the treatment of aneurysms
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
WO2002066070A1 (fr) 2002-08-29
PT1362600E (pt) 2008-07-09
JP2009102428A (ja) 2009-05-14
DE60225899T2 (de) 2009-04-09
JP3778357B2 (ja) 2006-05-24
EP1690544A2 (en) 2006-08-16
ES2307733T3 (es) 2008-12-01
US20040162251A1 (en) 2004-08-19
ATE390938T1 (de) 2008-04-15
JPWO2002066070A1 (ja) 2004-06-17
EP1362600A1 (en) 2003-11-19
US9012417B2 (en) 2015-04-21
TWI308492B (enExample) 2009-04-11
US20090105183A1 (en) 2009-04-23
EP1362600B1 (en) 2008-04-02
EP1690544B1 (en) 2017-09-13
EP1690544A3 (en) 2012-03-07
DE60225899D1 (de) 2008-05-15
EP1362600A4 (en) 2005-09-21
JP4987022B2 (ja) 2012-07-25
CY1108165T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
DK1362600T3 (da) Topisk anvendelse af NF-kB-attrapper til behandling af atopisk dermatitis
WO2002043652A3 (en) Anti-proliferative drugs
CY1109972T1 (el) Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας
BR0313627A (pt) Formulações farmacêuticas, processos para a preparação de formulação farmacêutica e método para o tratamento de dores
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
FR2866884B1 (fr) Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
WO2005092392A3 (en) Conjugated psychotropic drugs and uses thereof
EP2144608A4 (en) SUN PROTECTION COMPOSITIONS AND METHODS
EP1663959A4 (en) NEW AMIDINE COMPOUNDS FOR THE TREATMENT OF MICROBIAL INFECTIONS
MXPA03007903A (es) Sistema terapeutico transdermico altamente flexible con nicotina como ingrediente activo.
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
MXPA05010384A (es) Composiciones adherentes para el cuidado de la piel y articulos que tienen las composiciones adherentes para el cuidado de la piel colocadas encima.
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
FR2868784B1 (fr) Copolymere sequence, composition le comprenant et procede de traitement cosmetique
EE200300064A (et) Farmatseutiline kompositsioon C. pneumoniae pooltpõhjustatud infektsioonide raviks ja/või ennetamiseks, mahekompositsioon ja nende kasutamine
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
CA2441461A1 (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
BR0313570A (pt) Agente, e, uso do mesmo
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária